Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors von Shah, A.Y., Kotecha, R.R., Lemke, E.A., Chandramohan, A., Chaim, J.L., Msaouel, P., Xiao, L., Gao, J., Campbell, M.T., Zurita, A.J., Wang, J., Corn, P.G., Jonasch, E., Motzer, R.J., Sharma, P., Voss, M.H., Tannir, N.M.

Volltext

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis von Campbell, Matthew T., Bilen, Mehmet A., Shah, Amishi Y., Lemke, Emily, Jonasch, E., Venkatesan, A.M., Altinmakas, E., Duran, C., Msaouel, Pavlos, Tannir, N.M.

Volltext

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma von Ho, T H, Park, I Y, Zhao, H, Tong, P, Champion, M D, Yan, H, Monzon, F A, Hoang, A, Tamboli, P, Parker, A S, Joseph, R W, Qiao, W, Dykema, K, Tannir, N M, Castle, E P, Nunez-Nateras, R, Teh, B T, Wang, J, Walker, C L, Hung, M-C, Jonasch, E

Volltext

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma von Zurita, A.J., Jonasch, E., Wang, X., Khajavi, M., Yan, S., Du, D.Z., Xu, L., Herynk, M.H., McKee, K.S., Tran, H.T., Logothetis, C.J., Tannir, N.M., Heymach, J.V.

Volltext

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease von Jonasch, E., McCutcheon, I.E., Waguespack, S.G., Wen, S., Davis, D.W., Smith, L.A., Tannir, N.M., Gombos, D.S., Fuller, G.N., Matin, S.F.

Volltext

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies von Matrana, M.R, Duran, C, Shetty, A, Xiao, L, Atkinson, B.J, Corn, P, Pagliaro, L.C, Millikan, R.E, Charnsangave, C, Jonasch, E, Tannir, N.M

Volltext

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy von Richey, S.L., Culp, S.H., Jonasch, E., Corn, P.G., Pagliaro, L.C., Tamboli, P., Patel, K.K., Matin, S.F., Wood, C.G., Tannir, N.M.

Volltext

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis von Liu, X-D, Yao, J, Tripathi, D N, Ding, Z, Xu, Y, Sun, M, Zhang, J, Bai, S, German, P, Hoang, A, Zhou, L, Jonasch, D, Zhang, X, Conti, C J, Efstathiou, E, Tannir, N M, Eissa, N T, Mills, G B, Walker, C L, Jonasch, E

Volltext

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity von Shu, X, Hildebrandt, M A, Gu, J, Tannir, N M, Matin, S F, Karam, J A, Wood, C G, Wu, X

Volltext

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma von Jonasch, E., Hasanov, E., Corn, P.G., Moss, T., Shaw, K.R., Stovall, S., Marcott, V., Gan, B., Bird, S., Wang, X., Do, K.A., Altamirano, P.F., Zurita, A.J., Doyle, L.A., Lara, P.N., Tannir, N.M.

Volltext

Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials von Amini, B, Beaman, C B, Madewell, J E, Allen, P K, Rhines, L D, Tatsui, C E, Tannir, N M, Li, J, Brown, P D, Ghia, A J

Volltext

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors von Tannir, N.M., Naing, A., Papadopoulos, K.P., Wong, D.J., Korn, W.M., Aljumaily, R., Autio, K.A., Pant, S., Bauer, T.M., Drakaki, A., Daver, N., Hung, A., Oft, M., Leveque, J.

Volltext

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC):... von McDermott, D.F., Rini, B.I., Motzer, R.J., Tannir, N.M., Escudier, B., Kollmannsberger, C.K., Hammers, H.J., Porta, C., George, S., Donskov, F., Gurney, H.P., Grimm, M.-O., Harrison, M., Hutson, T.E., Doan, J., Yang, S., Rao, S., Mekan, S., Ambavane, A., Powles, T.

Volltext

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 von Rini, B.I., Tannir, N.M., Escudier, B., McDermott, D.F., Grimm, M.-O., Porta, C., Powles, T., Kollmannsberger, C.K., Gurney, H.P., Tykodi, S.S., Harrison, M., Heng, D.Y.C., Grünwald, V., Choueiri, T.K., Mekan, S., McHenry, M.B., Hammers, H.J., Motzer, R.J., George, S.

Volltext

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III Ch... von Tannir, N.M., Albigès, L., McDermott, D.F., Burotto, M., Choueiri, T.K., Hammers, H.J., Barthélémy, P., Plimack, E.R., Porta, C., George, S., Donskov, F., Atkins, M.B., Gurney, H., Kollmannsberger, C.K., Grimm, M.-O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B.I., Jiang, R., Desilva, H., Fedorov, V., Lee, C.-W., Motzer, R.J.

Volltext

Idiopathic Thrombocytopenic Purpura Following Successful Treatment of Acute Lymphoblastic Leukemia von Tannir, Near M., Kantarjian, Hagop

Volltext

Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma von Melkonian, Stephanie C, Wang, Xin, Gu, Jian, Matin, Surena F, Tannir, Nizar M, Wood, Christopher G, Wu, Xifeng

Volltext

964PLenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibito... von Wiele, A J, Ross, J, Chahoud, J, Lim, Z, Xiao, L, Campbell, M T, Shah, A Y, Zurita Saavedra, A, Jonasch, E, Tannir, N M

Volltext